Cytokinetics, Inc. : Cytokinetics to Present Clinical Trial Data Relating to Tirasemtiv in Patients with Myasthenia Gravis

 Cytokinetics, Inc. : Cytokinetics to Present Clinical Trial Data Relating to
                Tirasemtiv in Patients with Myasthenia Gravis

  Phase IIa data to be Presented at the 65^th Annual Meeting of the American
                             Academy of Neurology

South San Francisco, CA, March 13, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today  that an  Emerging Science  Session poster  presentation 
relating to  tirasemtiv is  scheduled  to be  presented  at the  65^th  Annual 
Meeting of the American Academy of Neurology  to be held March 16-23, 2013  at 
the San Diego Convention Center in San Diego, CA. 

Tirasemtiv is the  lead drug  candidate that  has emerged  from the  company's 
skeletal muscle contractility program.  Tirasemtiv selectively activates  the 
fast skeletal  muscle  troponin  complex  by  increasing  its  sensitivity  to 
calcium, which increases skeletal muscle  force in response to neuronal  input 
and delays the onset and reduces  the degree of muscle fatigue. Tirasemtiv  is 
currently being  evaluated  in BENEFIT-ALS,  an  international,  double-blind, 
randomized, placebo-controlled, Phase IIb clinical trial designed to  evaluate 
the safety, tolerability and potential  efficacy of this novel drug  candidate 
in patients with amyotrophic lateral sclerosis.

Emerging Science  Presentation at  the 65^th  Annual Meeting  of the  American 
Academy of Neurology

Title: A Study to Evaluate Efficacy, Safety and Tolerability of Single Doses
of Tirasemtiv in Patients with Myasthenia
Gravis
Presenter: Donald B. Sanders, MD, FAAN, Professor, Division of Neurology and
Founder of the Duke Myasthenia Gravis Clinic and Chair
Date:  Wednesday, March 20, 2013
Session: 5LB.001 - Emerging Science Session
Presentation and Poster Number: 009
Presentation Time: 6:09 PM (Pacific Time)
Poster on Display: 5:45 PM - 7:00 PM (Pacific Time)

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide  (excluding Japan)  to develop  and commercialize  omecamtiv 
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization  participation  rights.  Cytokinetics  is  independently 
developing tirasemtiv, a skeletal muscle  activator, as a potential  treatment 
for  diseases  and  conditions  associated  with  aging,  muscle  wasting   or 
neuromuscular dysfunction. Tirasemtiv is currently  the subject of a Phase  II 
clinical trials program and has been granted orphan drug designation and  fast 
track status by  the U.S. Food  and Drug Administration  and orphan  medicinal 
product designation  by  the  European  Medicines  Agency  for  the  potential 
treatment  of  amyotrophic  lateral  sclerosis,  a  debilitating  disease   of 
neuromuscular  impairment  in   which  treatment   with  tirasemtiv   produced 
potentially clinically relevant  pharmacodynamic effects in  Phase II  trials. 
All of these drug  candidates have arisen  from Cytokinetics' muscle  biology 
focused research activities  and are  directed towards  the cytoskeleton.  The 
cytoskeleton is a complex biological  infrastructure that plays a  fundamental 
role within every human cell. Additional information about Cytokinetics can be
obtained at www.cytokinetics.com.

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates.  Such 
statements are based on management's current expectations, but actual  results 
may differ materially due to  various risks and uncertainties, including,  but 
not limited to, potential difficulties or delays in the development,  testing, 
regulatory approval  and  production  of  Cytokinetics'  drug  candidates  and 
potential drug candidates that could  slow or prevent clinical development  or 
product approval, including risks  that current and  past results of  clinical 
trials or preclinical studies may not be indicative of future clinical  trials 
results and that Cytokinetics' drug  candidates and potential drug  candidates 
may have unexpected adverse side  effects or inadequate therapeutic  efficacy. 
For  further  information   regarding  these  and   other  risks  related   to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.

Contact:
Joanna (Jodi) L. Goldstein
Manager, Corporate Communications & Marketing
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1685169